Preventing Genetic Damage at the Cellular Level
Genotoxicity Testing assesses the potential of leachable substances from a medical device to induce genetic mutations or damage the cellular DNA. Because genetic alterations are closely linked to carcinogenesis and hereditary defects, these tests are mandatory for devices with prolonged or permanent contact with the human body.
1. Key Objectives
-
Detection of Mutagenicity: To identify whether substances can cause point mutations in the genetic code.
-
Assessment of Clastogenicity: To observe if the material induces structural chromosome breakage or numerical aberrations.
-
Early Carcinogenic Screening: Many carcinogens exhibit genotoxic properties; thus, these assays serve as a critical early warning system for cancer risk.
2. The Recommended Test Battery
Per ISO 10993-3, a single assay is insufficient. A "battery" of in vitro and sometimes in vivo tests is required:
-
Ames Test (Bacterial Reverse Mutation): Uses Salmonella strains to detect point mutations.
-
In Vitro Chromosomal Aberration Test: Examines mammalian cells for visible structural damage to chromosomes.
-
Mouse Lymphoma Assay (MLA): A versatile test capable of detecting both gene mutations and chromosomal changes.
-
Micronucleus Test: Identifies the presence of micronuclei, which are hallmarks of chromosomal fragments or whole chromosome loss.
3. Regulatory Significance of ISO 10993-3
Genotoxic effects are often considered non-threshold events, meaning even trace amounts can potentially be significant. Compliance with ISO 10993-3 ensures that a device’s chemical profile does not pose a long-term risk to the patient's genetic integrity.
Click to Pay
